Journal of Holistic Nursing
September 6, 2021
Rebecca H Lehto, Megan Miller, Jessica Sender
16 citations
Treatments for addressing psychiatric mental health issues in vulnerable patients with cancer are established. Yet, many patients persist with unrelenting psychological difficulties despite intervention. There is growing interest in the role of psilocybin-assisted psychotherapy for managing treatment-resistant mental health challenges in patients with cancer. Psilocybin is a naturally occurring...
Research, Society and Development
August 19, 2021
Frederico Marques Silveira, Amanda Pereira Mendes, Mayara Rodrigues Dos Santos et al.
1 citation
Cancer is not limited to the physical dimension, but it also affects the entire biopsychosocial context in which the patient is inserted, making him more susceptible to psychiatric disorders such as depression and anxiety. These often require pharmacological intervention, and the use of psilocybin, a substance found in mushroom species, is one of the alternatives considered today. The present...
Pharmaceuticals
August 12, 2021
Gniewko Więckiewicz, Iga Stokłosa, Magdalena Piegza et al.
30 citations
Despite many different kinds of substances available for depression treatment, depression itself still appears to be a clinical challenge. Recently, formerly illicit substances came to scientists’ attention, including lysergic acid diethylamide (LSD), psilocybin and dimethyltryptamine (DMT). Some studies suggest that these substances might be effective in depression treatment. The aim of this...
L'Encephale
August 1, 2021
Lucie Berkovitch, Bruno Romeo, Laurent Karila et al.
25 citations
Psychedelics are powerful psychoactive substances. Natural psychedelics have been used for millennia by human civilizations, in particular in Latin America, while synthetic psychedelics were discovered in the 50s, giving rise to a lot of research before they were prohibited. More recently, their therapeutic properties have been studied especially to help patients with psychiatric conditions,...
Life
July 29, 2021
Dominika Psiuk, Emilia Nowak, Krystian Cholewa et al.
13 citations
Due to an increasing number of depression diagnoses and limited effective treatments, researchers continue to explore novel therapeutic strategies for this disorder. Recently, interest has revolved around the use of serotonergic psychedelics to reduce the symptoms of depression. In this systematic review, we summarize the currently available knowledge on the safety and efficacy of psychedelic...
July 27, 2021
A mood disorder study published in the New England Journal of Medicine is a bullet unto itself. Use of escitalopram, not a placebo, for the comparison group—another rarity! And the results? Well, not better, but equivalent. Here comes big pharmaceutical company money.
July 5, 2021
Rosalind Watts
37 citations
preprint
"The Psilocybin for Depression: The ACE Manual '' describes the structure, procedures, and scripts used in the two Imperial College London studies (Psilodep) researching psilocybin treatment for major depression.
Journal of Psychiatric Research
July 1, 2021
Ashley N. Siegel, Shakila Meshkat, Katie Benitah et al.
101 citations
Psychedelics are a hallucinogenic class of psychoactive drugs with the primary effect of activating non-ordinary states of consciousness. Due to the positive preliminary findings of these drugs in the treatment of psychiatric disorders, the number of registered clinical studies has risen significantly. In this paper, clinical studies registered on clinicaltrials.gov that evaluate the treatment...
June 27, 2021
Annie M. Mccartney, Hugh McGovern, Alexander de Foe
preprint
Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to evaluate the current state of this...
OBM Neurobiology
June 24, 2021
Sarah-Catherine Rodan, Phillip Aouad, Iain S. Mcgregor et al.
10 citations
Anorexia Nervosa (AN) is a major health problem with one of the highest mortalities and treatment costs of any psychiatric condition. Cognitive behavioural therapy (CBT) is currently the most widely used treatment for AN in adults but provides remission rates ≤ 50%. Treatment drop-out is exceedingly high and those that persevere with treatment often relapse, causing increased risk of morbidity...